Insights Into Metastatic Castration-Resistant Prostate Cancer
Perspectives on current treatment practices regarding genetic testing in metastatic castration-resistant prostate cancer (mCRPC), first-line treatment of mCRPC, and management of progressive and/or symptomatic mCRPC
Northeast – December 15, 2020
Faculty Chair
Daniel Petrylak, MD
Yale University, CT, US
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of mCRPC was held on December 15, 2020
- Disease state and data presentations were developed in conjunction with Daniel Petrylak, MD, a medical expert from Yale School of Medicine
- Insights into genetic testing methods and therapies were obtained, with a particular focus on olaparib, rucaparib, genetic testing (somatic/germline); BRCA, HRR, and PALB2 mutations
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and moderated discussion
- Attendees of the roundtable represented community oncologists from New Jersey, Pennsylvania, Vermont, Massachusetts, and New York
